-
Sector Analysis
NewWestern Europe Food Market Opportunities, Trends, Growth Analysis and Forecast to 2028
Western Europe Food Market Report Overview The Western Europe food market size was $1.00 billion in 2023 and will grow at a CAGR of more than 3% during 2023-2028. The Western Europe food market research report covers a comprehensive overview of consumption of various food products by sector, for the period 2018-2028. To help market players understand future market opportunities, the report covers high-potential countries based on key factors such as economic development, governance, socio-demography, and technological infrastructure. Western Europe...
-
Sector Analysis
NewMiddle East and Africa (MEA) Food Market Opportunities, Trends, Growth Analysis and Forecast to 2028
MEA Food Market Report Overview The MEA food market size was $277.9 billion in 2023 and will grow at a CAGR of more than 3% during 2023-2028. The affluent population in the Middle East will play an important role in the industry’s growth. Furthermore, consumers’ purchasing power in Africa will increase, stimulating growth in their food purchases thereby driving the market. MEA Food Market Outlook 2023-2028 ($ Billion) Buy the Full Report for More Insights into the MEA Food Market...
-
Thematic Analysis
NewCybersecurity in Agriculture – Thematic Intelligence
Cybersecurity is the practice of defending computers, servers, mobile devices, electronic systems, networks, and data from malicious attacks. According to GlobalData forecasts, the cybersecurity industry will be worth $290 billion by 2027, growing at a compound annual growth rate (CAGR) of 13% between 2022 and 2027.
-
New
Net Present Value Model: Acelyrin Inc’s Izokibep
Empower your strategies with our Net Present Value Model: Acelyrin Inc's Izokibep report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Merck & Co Inc’s Ulevostinag
Empower your strategies with our Net Present Value Model: Merck & Co Inc's Ulevostinag report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: GSK plc’s Belrestotug
Empower your strategies with our Net Present Value Model: GSK plc's Belrestotug report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: AstraZeneca Plc’s Anselamimab
Empower your strategies with our Net Present Value Model: AstraZeneca Plc's Anselamimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Eli Lilly and Co’s Eltrekibart
Empower your strategies with our Net Present Value Model: Eli Lilly and Co's Eltrekibart report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Avalo Therapeutics Inc’s Quisovalimab
Empower your strategies with our Net Present Value Model: Avalo Therapeutics Inc's Quisovalimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Net Present Value Model: Verastem Inc’s Avutometinib Potassium
Empower your strategies with our Net Present Value Model: Verastem Inc's Avutometinib Potassium report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.